The unanticipated results from the CANTOS trial together with the preclinical findings on the role of IL-1β in lung cancer have led to the design of a number of clinical trials that are currently exploring IL-1β as a therapeutic target in lung cancer (Table 2). This evidence concerns the gene IL1B and lung cancer.